| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:AEZS-108
CAS:139570-93-7
Purity:98% Remarks:Reach out to us for more information about custom solutions.
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Email: |
|
| Products Intro: |
Product Name:AN152
CAS:139570-93-7
Purity:99% HPLC Package:50Mg,100Mg,500Mg,1g,5g,10g,50g,100g,500g,1kg Remarks:XYA1118
|
| Company Name: |
AdooQ BioScience, LLC
|
| Tel: |
+1 (866) 930-6790 |
| Email: |
info@adooq.com |
| Products Intro: |
Product Name:AEZS-108
CAS:139570-93-7
Purity:98% Package:5mg;10mg;25mg;50mg;100mg;250mg;500mg;1g
|
| Company Name: |
LETOPHARM LIMITED
|
| Tel: |
+86-21-5821 5861 |
| Email: |
sales@letopharm.com |
| Products Intro: |
Product Name:AN152
CAS:139570-93-7
|
|
| Product Name: | AN152 | | Synonyms: | AN152;AEZS 108;ZOPTARELIN DOXORUBICIN;Batifiban;OOUACICUAVTCEC-LZHWUUGESA-N;AEZS 108; AEZS108; ZOPTARELIN DOXORUBICIN; AN 152; AN-152; AN152;Luteinizing hormone-releasing factor (swine), 6-[N6-[5-[2-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-oxoethoxy]-1,5-dioxopentyl]-D-lysine]- | | CAS: | 139570-93-7 | | MF: | C91H117N19O26 | | MW: | 1893.01 | | EINECS: | | | Product Categories: | | | Mol File: | 139570-93-7.mol |  |
| | AN152 Chemical Properties |
| density | 1.57±0.1 g/cm3(Predicted) | | pka | 7.34±0.60(Predicted) |
| | AN152 Usage And Synthesis |
| Uses | Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro[1]. | | in vivo | Zoptarelin doxorubicin (AN-152) inhibits tumor growth in glioblastoma xenograft mice[1]. | Animal Model: | Female nude mice (injected in the flanks with 1×106 glioblastoma U-87 MG cells)[1] | | Dosage: | 413 nM/20g | | Administration: | i.v.; once weekly; for 6 weeks | | Result: | Significantly inhibited tumor growth compared to the control. |
| | References | [1] Jaszberenyi M, et al. Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Oncotarget. 2013 Mar;4(3):422-32. DOI:10.18632/oncotarget.917 |
| | AN152 Preparation Products And Raw materials |
|